Non-small cell lung cancer Global Market Report 2025_Segment

Non-small cell lung cancer Global Market Report 2025

Non-small cell lung cancer Global Market Report 2025_Regional

The Business Research Company's Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, December 4, 2025 /EINPresswire.com/ -- Non-Small Cell Lung Cancer (NSCLC) Market to Surpass $64 billion in 2029. In comparison, the Lung Cancer Drugs market, which is considered as its parent market, is expected to be approximately $79 billion by 2029, with non-small cell lung cancer (NSCLC) to represent around 81% of the parent market. Within the broader Pharmaceuticals industry, which is expected to be $2,355 billion by 2029, the non-small cell lung cancer (NSCLC) market is estimated to account for nearly 3% of the total market value.

Which Will Be the Biggest Region in The Non-Small Cell Lung Cancer (NSCLC) Market in 2029?
North America will be the largest region in the non-small cell lung cancer (NSCLC) market in 2029, valued at $27,249 million. The market is expected to grow from $16,678 million in 2024 at a compound annual growth rate (CAGR) of 10%. The strong growth can be attributed to the rise in advancements in targeted therapies and immunotherapies and increased healthcare expenditure.

Which Will Be The Largest Country In The Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029?
The USA will be the largest country in the non-small cell lung cancer (NSCLC) market in 2029, valued at $24,435 million. The market is expected to grow from $15,006 million in 2024 at a compound annual growth rate (CAGR) of 10%. The strong growth can be attributed to the increasing research and development in healthcare and increasing product innovations.

Request a free sample of the Non-Small Cell Lung Cancer Market report:
https://www.thebusinessresearchcompany.com/sample_request?id=13232&type=smp

What will be Largest Segment in the non-small cell lung cancer (NSCLC) Market in 2029?
The non-small cell lung cancer (NSCLC) market is segmented by type into squamous cell carcinoma, large cell carcinoma, adenocarcinoma and other types. The adenocarcinoma market will be the largest segment of the non-small cell lung cancer (NSCLC) market segmented by type accounting for 50% or $31,944 million of the total in 2029. The adenocarcinoma market will be supported by increasing cases among both smokers and non-smokers, rising prevalence in women compared to other NSCLC types, strong adoption of targeted therapies and precision medicine, growing number of biomarker-driven treatment options, improved accessibility of immunotherapies, expansion of cancer care centers globally, and enhanced survival rates due to combination therapy approaches.

The non-small cell lung cancer (NSCLC) market is segmented by therapy into radiation therapy, chemotherapy, targeted therapy, immunotherapy and other therapies. The immunotherapy market will be the largest segment of the non-small cell lung cancer (NSCLC) market segmented by therapy, accounting for 31% or $ 19,745 million of the total in 2029. The immunotherapy market will be supported by its continued role as a first-line treatment in advanced and metastatic NSCLC, widespread availability of generic chemotherapy drugs ensuring affordability, rising use in combination with targeted and immunotherapies to improve survival outcomes, established treatment protocols and guidelines supporting chemotherapy regimens, ongoing demand in regions with limited access to advanced therapies, increasing awareness programs highlighting chemotherapy benefits, and supportive healthcare infrastructure in emerging economies

The non-small cell lung cancer (NSCLC) market is segmented by distribution channel into hospital pharmacy, online pharmacy and other distribution channels. The hospital pharmacy market will be the largest segment of the non-small cell lung cancer (NSCLC) market segmented by distribution channel, accounting for 69% or $44,013 million of the total in 2029. The hospital pharmacy market will be supported by the availability of advanced cancer treatment drugs in inpatient settings, increasing patient admissions for chemotherapy and radiotherapy, presence of skilled oncology pharmacists, government and insurance coverage for hospital-based treatments, rising focus on centralized drug dispensing for cancer patients, and improvements in hospital infrastructure supporting oncology care.

What is the expected CAGR for the non-small cell lung cancer (NSCLC) Market leading up to 2029?
The expected CAGR for the non-small cell lung cancer (NSCLC) Market leading up to 2029 is 11%.

What Will Be The Growth Driving Factors In The Global Non-small Cell Lung Cancer (NSCLC) Market In The Forecast Period?
The rapid growth of the global non-small cell lung cancer (NSCLC) market leading up to 2029 will be driven by the following key factors that are expected to reshape oncology treatment paradigms, diagnostics, and patient outcomes worldwide.

Increasing Research And Development In Healthcare - The increasing research and development in healthcare will become a key driver of growth in the non-small cell lung cancer (NSCLC) market by 2029. It leads to the discovery of new targeted therapies, immunotherapies, and precision medicine approaches, which improve patient outcomes. Advanced R&D also accelerates clinical trials and regulatory approvals for novel drugs. As a result, the increasing research and development in healthcare is anticipated to contributing to a 2.0% annual growth in the market.

Rise In Public Awareness Campaigns - The growing focus on Public Awareness Campaigns will emerge as a major factor driving the expansion of the non-small cell lung cancer (NSCLC) market by 2029. It leads to more individuals seeking screenings and medical consultations, resulting in earlier diagnosis. Early detection increases the demand for advanced treatments and therapies. Additionally, awareness drives funding and support for research, accelerating the development and adoption of innovative non-small cell lung cancer (NSCLC) treatments. Consequently, the rise In Public Awareness Campaigns is projected to contributing to a 1.5% annual growth in the market.

Rise In Advancements In Targeted Therapies And Immunotherapies - The expanding advancements in targeted therapies and immunotherapies processes will serve as a key growth catalyst for the non-small cell lung cancer (NSCLC) market by 2029, These therapies often have fewer side effects compared to traditional chemotherapy, making them more appealing to patients and clinicians. As a result, more patients are likely to adopt these treatments, increasing demand. Therefore, this growing advancements in targeted therapies and immunotherapies is projected to supporting to a 1.0% annual growth in the market.

Increased Healthcare Expenditure - The increasing emphasis on Healthcare Expenditure will become a significant driver contributing to the growth of the non-small cell lung cancer (NSCLC) market by 2029 This improves early detection and access to targeted treatments, which enhances patient outcomes. Higher spending also supports research and development, fueling the introduction of new drugs and immunotherapies. Consequently, the rising adoption of Healthcare Expenditure is projected to contributing to a 0.7 % annual growth in the market.

Access the detailed Non-Small Cell Lung Cancer (NSCLC) Market report here:
https://www.thebusinessresearchcompany.com/market-insights/non-small-cell-lung-cancer-nsclc-market-insights-2025

What Are The Key Growth Opportunities In The Non-small Cell Lung Cancer (NSCLC) Market in 2029?
The most significant growth opportunities are anticipated in the adenocarcinoma non-small cell lung cancer (NSCLC) market, immunotherapy based non–small cell lung cancer (NSCLC) market and non–small cell lung cancer hospital-pharmacy services market. Collectively, these segments are projected to contribute over $45 billion in market value by 2029, driven by rising global lung cancer incidence, increasing adoption of precision oncology, and rapid advancements in targeted and immunotherapy treatments. the integration of molecular diagnostics and biomarker-based screening is enabling more accurate subtype identification, leading to better treatment selection and improved patient outcomes. furthermore, growing investment by pharmaceutical and biotechnology companies in NSCLC–adenocarcinoma drug pipelines, coupled with accelerated regulatory approvals and expanding access to novel therapeutics in emerging markets, will reinforce market momentum.

The global non–small cell lung cancer hospital-pharmacy services market is projected to grow by $17,590 million, the global adenocarcinoma non-small cell lung cancer (NSCLC) market by $15,120 million, the global immunotherapy based non–small cell lung cancer (NSCLC) market by $12,025 million over the next five years from 2024 to 2029.

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.